View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 18, 2020

Coronavirus: Chloroquine yields positive data in Covid-19 trial

Early data from clinical trials being performed in China has revealed that chloroquine phosphate could help treat the new coronavirus disease, Covid-19.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.

Early data from clinical trials being performed in China has revealed that chloroquine phosphate could help treat the new coronavirus disease, Covid-19.

China National Center for Biotechnology Development deputy head Sun Yanrong said that chloroquine, an anti-malarial medication, was selected after several screening rounds of thousands of existing drugs.

Xinhua reported that the drug is undergoing clinical trials in more than ten hospitals in Beijing, Guangdong province, and Hunan province.

Chloroquine data from Covid-19 trials

Data from the drug’s studies showed ‘certain curative effect’ with ‘fairly good efficacy’.

According to Sun, patients treated with chloroquine demonstrated a better drop in fever, improvement of lung CT images, and required a shorter time to recover compared to parallel groups.

The percentage of patients with negative viral nucleic acid tests was also higher with the anti-malarial drug.

Chloroquine has so far showed no obvious serious adverse reactions in the more than 100 participants in the trials.

The China National Center for Biotechnology Development head Zhang Xinmin said that chloroquine is one of the three drugs that have a promising profile against the new coronavirus, reported China Daily.

The remaining two drugs are anti-flu medicine favipiravir and Gilead’s investigational anti-viral candidate remdesivir.

Favipiravir is currently in a 70-patient trial in Shenzhen, Guangdong province, while remdesivir is under evaluation at more than ten medical institutions in Wuhan.

WSJ noted that remdesivir’s trials are progressing slower than expected due to the lack of eligible coronavirus patients. Around 200 of the trial’s target of 700 participants have been enrolled after ten days.

Japan to trial HIV medication

Japan chief cabinet secretary Yoshihide Suga has announced plans to conduct clinical trials of an existing HIV medication for the treatment of Covid-19.

Suga was quoted by Reuters as saying: “We’re currently preparing to start clinical trials using HIV medication on the novel coronavirus.”

The chief cabinet secretary did not comment on the time period required for the drug’s approval. Similar studies are already underway in China.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena